Immunovant to Host Investor Webcast at 8:00 AM ET on Wednesday, March 19 to Review Results from Batoclimab Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Programs
Immunovant (Nasdaq: IMVT) has announced an upcoming investor webcast scheduled for Wednesday, March 19, 2025, at 8:00 AM ET. The presentation will focus on revealing results from two significant clinical trials: the Phase 3 study of batoclimab in Myasthenia Gravis (MG) and initial findings from the Phase 2b study in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP).
The webcast will feature presentations from Pete Salzmann, M.D., MBA, Immunovant's Chief Executive Officer, alongside Matt Gline, Chief Executive Officer of Roivant. Interested participants can access the live webcast through registration, and it will also be available in the News & Events section of Immunovant's website. A replay option will be provided immediately after the event.
Immunovant (Nasdaq: IMVT) ha annunciato un prossimo webcast per investitori programmato per mercoled矛 19 marzo 2025, alle 8:00 AM ET. La presentazione si concentrer脿 sulla rivelazione dei risultati di due significativi studi clinici: lo studio di Fase 3 di batoclimab nella Miastenia Grave (MG) e i risultati iniziali del studio di Fase 2b nella Neuropatia Infiammatoria Cronica Demielinizzante (CIDP).
Il webcast presenter脿 interventi di Pete Salzmann, M.D., MBA, Amministratore Delegato di Immunovant, insieme a Matt Gline, Amministratore Delegato di Roivant. I partecipanti interessati possono accedere al webcast dal vivo tramite registrazione, e sar脿 anche disponibile nella sezione Notizie ed Eventi del sito web di Immunovant. Un'opzione di replay sar脿 fornita immediatamente dopo l'evento.
Immunovant (Nasdaq: IMVT) ha anunciado un pr贸ximo webcast para inversores programado para mi茅rcoles 19 de marzo de 2025, a las 8:00 AM ET. La presentaci贸n se centrar谩 en revelar los resultados de dos ensayos cl铆nicos significativos: el estudio de Fase 3 de batoclimab en Miastenia Gravis (MG) y los hallazgos iniciales del estudio de Fase 2b en Neuropat铆a Inflamatoria Cr贸nica Desmielinizante (CIDP).
El webcast contar谩 con presentaciones de Pete Salzmann, M.D., MBA, Director Ejecutivo de Immunovant, junto a Matt Gline, Director Ejecutivo de Roivant. Los participantes interesados pueden acceder al webcast en vivo a trav茅s de la registraci贸n, y tambi茅n estar谩 disponible en la secci贸n de Noticias y Eventos del sitio web de Immunovant. Se proporcionar谩 una opci贸n de repetici贸n inmediatamente despu茅s del evento.
Immunovant (Nasdaq: IMVT)电� 2025雲� 3鞗� 19鞚� 靾橃殧鞚� 鞓れ爠 8:00 ET鞐� 鞓堨爼霅� 韴瀽鞛� 鞗轨簮鞀ろ姼毳� 氚滍憸頄堨姷雼堧嫟. 氚滍憸电� 霊� 臧�歆� 欷戩殧頃� 鞛勳儊 鞁滍棙 瓴瓣臣毳� 瓿店皽頃樀鐢 雿� 齑堨爯鞚� 毵烄稖 瓴冹瀰雼堧嫟: 欷戩 攴茧霠レ(MG)鞐愳劀鞚� batoclimab鞐� 雽�頃� 3靸� 鞐瓣惮鞕赌 毵岇劚 鞐检靹� 韮堨垬齑堨劚 雼る皽鞁犼步氤戩(CIDP)鞐愳劀鞚� 2b靸� 鞐瓣惮鞚� 齑堦赴 瓴瓣臣.
鞗轨簮鞀ろ姼鞐愳劀电� Pete Salzmann, M.D., MBA, Immunovant鞚� CEO鞕赌 Matt Gline, Roivant鞚� CEO臧� 氚滍憸頃� 鞓堨爼鞛呺媹雼�. 甏�鞁� 鞛埖鐢 彀戈皜鞛惖鐢 霌彪鞚� 韱淀暣 鞁れ嫓臧� 鞗轨簮鞀ろ姼鞐� 鞝戧芳頃� 靾� 鞛堨溂氅�, Immunovant 鞗轨偓鞚错姼鞚� 雺挫姢 氚� 鞚措菠韸� 靹轨厴鞐愳劀霃� 鞚挫毄頃� 靾� 鞛堨姷雼堧嫟. 鞚措菠韸� 歆來泟 鞛儩 鞓奠厴鞚� 鞝滉车霅╇媹雼�.
Immunovant (Nasdaq: IMVT) a annonc茅 un prochain webinaire pour investisseurs pr茅vu pour mercredi 19 mars 2025, 脿 8h00 ET. La pr茅sentation se concentrera sur la r茅v茅lation des r茅sultats de deux essais cliniques significatifs : l'茅tude de Phase 3 de batoclimab dans la myasth茅nie grave (MG) et les r茅sultats pr茅liminaires de l'茅tude de Phase 2b dans la neuropathie d茅my茅linisante inflammatoire chronique (CIDP).
Le webinaire comprendra des pr茅sentations de Pete Salzmann, M.D., MBA, PDG d'Immunovant, ainsi que de Matt Gline, PDG de Roivant. Les participants int茅ress茅s peuvent acc茅der au webinaire en direct via une inscription, et il sera 茅galement disponible dans la section Actualit茅s et 脡v茅nements du site Web d'Immunovant. Une option de rediffusion sera fournie imm茅diatement apr猫s l'茅v茅nement.
Immunovant (Nasdaq: IMVT) hat ein bevorstehendes Investor-Webcast angek眉ndigt, das f眉r Mittwoch, den 19. M盲rz 2025, um 8:00 Uhr ET geplant ist. Die Pr盲sentation wird sich auf die Offenlegung der Ergebnisse von zwei bedeutenden klinischen Studien konzentrieren: der Phase-3-Studie zu batoclimab bei Myasthenia Gravis (MG) und den ersten Ergebnissen der Phase-2b-Studie zur chronischen entz眉ndlichen demyelinisierenden Polyneuropathie (CIDP).
Das Webcast wird Pr盲sentationen von Pete Salzmann, M.D., MBA, CEO von Immunovant, und Matt Gline, CEO von Roivant, beinhalten. Interessierte Teilnehmer k枚nnen 眉ber eine Registrierung auf das Live-Webcast zugreifen, das auch im Bereich Nachrichten und Veranstaltungen auf der Website von Immunovant verf眉gbar sein wird. Eine Wiederholungsoption wird unmittelbar nach der Veranstaltung bereitgestellt.
- None.
- None.
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP.
Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call.
Webcast Details
The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click to register for the event. The live webcast will also be available under the section of Immunovant鈥檚 website. A replay of the event and presentation will be available immediately following the event.
About Immunovant, Inc.
Immunovant, Inc. is a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases. As a trailblazer in anti-FcRn technology, the Company is developing innovative, targeted therapies to meet the complex and variable needs of people with autoimmune diseases. For additional information on the Company, please visit .
Contact:
Renee Barnett, MBA
Chief Financial Officer
Immunovant, Inc.
FAQ
When will Immunovant (IMVT) present its batoclimab Phase 3 MG study results?
What clinical trial results will IMVT discuss in the March 19 webcast?
How can investors access the IMVT March 19 webcast?
Who will be presenting at the IMVT investor webcast on March 19?
